Epidemiology of HPV in HIV-Positive and HIV-Negative Fertile Women in Cameroon, West Africa by Desruisseau, Andrew J. et al.
Hindawi Publishing Corporation
Infectious Diseases in Obstetrics and Gynecology
Volume 2009, Article ID 810596, 6 pages
doi:10.1155/2009/810596
Clinical Study
Epidemiologyof HPV in HIV-Positive and HIV-Negative Fertile
Women in Cameroon, West Africa
AndrewJ. Desruisseau,1 Delf Schmidt-Grimminger,2,3 andEdithWelty4
1Division of Infectious Diseases, Department of Internal Medicine, Meharry Medical College,
1005 Dr. DB Todd Jr Boulevard, Nashville, TN 37208, USA
2Department of Obstetrics and Gynecology, Sanford School of Medicine, The University of South Dakota,
Vermillion, Sioux Falls, SD 57105, USA
3Clinical Research Division, Avera Research Institute, Sioux Falls, SD 57105, USA
4Cameroon Baptist Convention Health Board, Bamenda, Cameroon
Correspondence should be addressed to Andrew J. Desruisseau, adesruisseau@mmc.edu
Received 3 April 2009; Accepted 14 December 2009
Recommended by Faustino R. P´ erez-L´ opez
Background. HPV types vary by country and HIV status. There are no data on the prevalent HPV genotypes from Cameroon.
Methods.We conducted across-sectional, observational studyon65 Cameroonian women. Samples were sent for HPV genotyping
and Thin Prep analyses. Results. 41 out of 61 samples tested (67.2%) had HPV subtypes detected. The most common high risk
typesencounteredwere:45(24.6%)and58(21.5%).HIV-positivewomenweremorelikelytotestpositiveforanyHPV(P = .014),
have more than one HPV subtype (P = .003), and to test positive for the high risk subtypes (P = .007). Of those with high risk
HPV, HIV-positive women were more likely to have Thin Prep abnormalities than HIV-negative women (P = .013). Conclusions.
Oncogenic HPV subtypes 45 and 58 were more prevalent than those subtypes carried in the quadrivalent vaccine. Further studies
are needed to assess whether the current vaccine will be eﬀective in this region.
Copyright © 2009 Andrew J. Desruisseau et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Cervical cancer is the second most common cancer in
women worldwide, but it is the ﬁrst in most developing
countries, where 80% of cases occur [1] and only 5% of
the at-risk population are screened [2, 3]. Further, cervical
cancer is the leading cancer-related cause of death in
African women [4]. Certain human papillomavirus (HPV)
genotypes, such as HPV 16 and 18, have clearly been shown
to be obligate causative agents in the development of cervical
cancer [5]. Only women with persistent infection with
oncogenic subtypes develop cervical cancer.
There are at least 15 high-risk (oncogenic) subtypes of
HPV [6]. Overall, HPV-16 and HPV-18 account for approx-
imately 70% of all cervical cancer diagnosed worldwide each
year [5, 7]. HPV genotypes 6 and 11 are associated with
genital warts (condyloma aciminata) and are not linked to
cervicalcanceroritsprecursorlesions.SeveralHPVvaccines,
including the now commercially available vaccine against
HPV genotypes 6, 11, 16, and 18, have been shown to reduce
the acquisition of infection and clinical disease caused by
these HPV genotypes and likely will lead to reductions in
cervical cancer and its precursor lesions [8–10].
HPV genotypes, however, diﬀer greatly in their geo-
graphic distribution. In sub-Saharan Africa, for instance,
where two thirds of the world’s HIV-infected population
live, HPV types vary by country and HIV status and diﬀer
signiﬁcantly from HPV types seen in other regions of
the world, possibly in part due to geographic and genetic
variation in HLA haplotypes [11–15]. Multiple prospective
studies have demonstrated that women with HIV infection
are much more likely than HIV-negative women to have
persistent HPV, often with oncogenic subtypes [16–18].
It has been estimated that a vaccine against HPV types
16 and 18 would theoretically prevent 71% of cervical
cancers worldwide, but would preferentially favor Asia and2 Infectious Diseases in Obstetrics and Gynecology
North America over Africa and South America [14]. To
our knowledge, there are no data in Cameroon on HPV
prevalence or genotypes.
This pilot study seeks to describe the prevalence of
HPV genotypes in HIV-positive and HIV-negative fertile
Cameroonian women, to determine risk factors for HPV
utilizing a culturally appropriate questionnaire and to assess
the association of HPV types, squamous intraepithelial
lesions (SIL), HIV, and other reproductive tract infections.
2.MaterialsandMethods
2.1. Study Population and Setting. This study was approved
by both the institutional review board of Meharry Medical
College and the Cameroon Baptist Convention Health Board
(CBCHB). Between June 2005 and March 2006 sixty-ﬁve
women age eighteen and over were enrolled from two
CBCHBclinicalsitesBaptistHospitalMutengeneandEtoug-
Ebe clinic in Yaounde. Women were recruited from both
antenatal clinics and existing HIV positive women’s support
groups. Women were excluded if they had never been
pregnant, had a hysterectomy, were in active labor, had
abnormal bleeding, had placenta previa, or were unwilling
to undergo HIV testing. The study was explained to patients
either in English, French, or Pidgin English. Similarly,
informedconsentwasobtainedinEnglishorFrenchbyclinic
nurses or midwives.
Participants were then asked to complete a questionnaire
designed to elicit demographic characteristics, obstetric,
contraceptive and sexual history, and current genital tract
symptoms. General, pelvic, and speculum examination and
sample collection were performed. Only support group
mothers also underwent bimanual exams. Women, and
their partners if necessary, were treated free of charge
for reproductive tract infections (RTIs) when clinically
indicated in accordance with World Health Organization
published guidelines [19]. Participants were counseled on
low-risk sexual behavior and provided with contraceptive
counseling,and/orcondomsifneeded.Returnappointments
and referrals were made as appropriate.
2.2. Samples Taken and Laboratory Methods
2.2.1. Cervical Mucus Samples. An ophthalmic sponge,
Zyomed Treace (Orlando, FL), was placed directly into the
cervical os. The spears were allowed to absorb cervical secre-
tions for approximately 30 seconds after which time they
were placed in an eppendorf tube and immediately placed on
ice, before they were transported on dry ice to the University
ofSouthDakotaforpossiblelatercytokineanalysisunderthe
direction of Dr. Delf Schmidt-Grimminger.
2.2.2.CervicalCytology. Afterintroductionofaclean,nonlu-
bricatedspeculum,theendocervicalsecretionswerecollected
as previously described in [20]w i t ha nA y r e ss p a t u l aa n d
cervical brush (or Dacron swab, if the patient was in the last
trimester of pregnancy) and placed it in PreservCyt (Cytyc
Corporation, Marlborough, MA). Thin Prep smears were
sent to the University of Kansas Medical Center, where they
were reviewed by a cytotechnologist under the direction of
Dr. Patricia Thomas, M.D., a board certiﬁed pathologist.
Thin prep abnormalities were classiﬁed according to the
Bethesda classiﬁcation system [21]. Testing for Neisseria
gonorrhoeae (NG) and Chlamydia trachomatis (CT) was
performed oﬀ of the Thin Prep sample as previously
described [22].
2.2.3. HPV PCR. Next, a sample for HPV testing was
collected with a cervical brush or Dacron swab, placed in a
Specimen Treatment Medium (STM; Digene Corporation,
Silver Spring, MD), and sent to the South Dakota Health
Research Foundation at the University of South Dakota,
where the HPV typing proceeded under the direction of Dr.
Delf Schmidt-Grimminger. An aliquot of the cervical sample
w a sp r o c e s s e da sd e s c r i b e dp r e v i o u s l y[ 23]. Brieﬂy, the
sample was precipitated and centrifuged, and the pellet dried
and resuspended. HPV detection and typing was carried out
usingapolymerasechainreaction-(PCR-)basedreverse-line
strip test for HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 40,
42, 45, 51–59, 66, 68, 73, 82, 83, and 84. B-globin was used
as an internal control as previously described in [24]. If the
participants consented, any residual specimens were stored
for possible additional testing related to reproductive tract
infections.
All transported specimens were frozen at 0 degrees
Celsiusduetologisticalproblemsandshippedat−20Cusing
dry ice according to international standards.
2.2.4. Additional Testing. Only if a patient complained of,
or had signs of an abnormal vaginal discharge or pelvic
infection, did we collect a vaginal pool specimen and place
it in a test tube containing saline and send it to the on site
lab to test for pH, wet saline preparation for T.v aginalis
and bacterial vaginosis, and potassium hydroxide (KOH)
prep for Candida. Bacterial vaginosis was deﬁned as the
presence of “clue cells” (epithelial cells completely covered
with coccobacilli to the extent that the cell borders are
obscured) constituting more than 20% of vaginal epithelial
cells per high power ﬁeld, and a pH of >4.5. All identiﬁed
infections were treated free of charge according to WHO
guidelines [19].
2.2.5. Serology. All participants without documentation of
HIV or syphilis tests within 6 months underwent testing
after pretest counseling. A serial testing protocol of up to
3 rapid HIV tests was used to determine HIV status as
previously described in [25]. Our lab used the Determine
HIV-1/2 (Abbott Laboratories, Tokyo, Japan) and the Deter-
mine Syphilis test, both of which produce results in 15
minutes. Patients with a negative Determine HIV result were
counseled as negative, were told about the “window period,”
and advised to have a repeat HIV test in 3–6 months. The
laboratory performed a SD BIOLINE HIV 1/2 3.0 rapid HIV
test (Standard Diagnostics, Inc., Kyonggi-do, Korea) on all
patients with a positive Determine test. If Determine and
Bioline tests were both positive, the patient was posttestInfectious Diseases in Obstetrics and Gynecology 3
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Figure 1: Low risk HPV type distribution.
counseled as positive. If Determine and Bioline test results
werediscrepant,thelaboratoryperformeda3rd“tiebreaker”
test (Hexagon HIV, Human GmbH, Germany) and the
patient was counseled according to the result of that test.
2.3. Data Analysis. Data were analyzed using SPSS 15.0
(SPSS Inc, Chicago, IL, USA). Simple frequency analyses,
Fisher’s exact test, and Chi-square tests were used. P-values
<.05 were considered signiﬁcant.
3. Results
Sixty-ﬁve women were enrolled in the study, 36 in the ante-
natalgroupand29inthesupportgroup.Themedianagewas
27 years in the antenatal group and 29 in the support group,
respectively.8.3%oftheantenatalparticipantstestedpositive
for HIV while 100% of the support group participants tested
HIV positive. The women did not diﬀer with respect to
education, marriage status, husband’s number of wives, age
at sexual debut, or cell phone ownership which was used
as a surrogate marker for income. However, over 50% of
theantenatalparticipants reportedneverusingcondomsand
over 80% reported never or only seldom using condoms
during sex. Similarly, only 35% of known HIV positive
women participants from the support group reported using
condoms often (Table 1).
Overall, out of the 65 women who signed consent forms,
4 had no evidence of specimens in their transport media. 41
ofthe61samplestested(67.2%)hadHPVsubtypesdetected.
Themostc o mmo nlo wrisktypesd et ect edouto fallanalyz ed
specimens were: 62 (20.0%), 11 (18.5%), 6 (15.4%), 70
(12.3%), and 61 (10.8%). The most common high risk types
encountered were: 45 (24.6%) and 58 (21.5%). The data is
presented by frequency of HPV type detected as a percentage
of all women in the study (HPV positive and negative) as
shown in Figures 1 and 2.
Thirty-ﬁve out of the 41 women (85.4%) who tested
positiveforHPVhadmorethanoneHPVsubtypeidentiﬁed,
while 32 out of 41 (78%) had at least one high risk subtype
identiﬁed. Twenty-eight out of 41, or 68.3%, with HPV
isolated had subtype 6, 11, 16, or 18 which are currently
carried in the commercially available HPV vaccine. Those
who tested positive for the high risk subtypes carried in the
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Figure 2: High risk HPV type distribution.
current vaccine (subtypes 16 or 18) totaled 7 out of 41, or
17.1% (see Table 2).
Incomparing HIV-negative toHIV-positive participants,
HIV positive women were more likely to have tested positive
for any HPV, have more than one HPV subtype, and to test
positive for the high risk HPV subtypes than their HIV-
negative counterparts when analyzed using the Chi-Square
statistic with a signiﬁcant P-value deﬁned as <.05. They were
also more likely to have one of the HPV subtypes covered in
the current quadrivalent HPV vaccine, although not when
including subtypes 16 and 18 only.
Atypical squamous cells of unknown signiﬁcance
(ASCUS), low grade squamous intraepithelial lesions
(LGSILs), and high grade intraepithelial lesions (HGILs)
represent increasing degrees of HPV-related cellular change
and are precancerous lesions. Women who were HIV
positive with high risk HPV were more likely than HIV
negative women with high-risk HPV to have abnormalities
on thin prep evaluation, even after controlling for the
eﬀect of high risk HPV on thin prep abnormalities using
Chi-Square analysis (P-value for HIV positive .013, for HIV
negative .235) (Table 3). Surprisingly, we did not encounter
any high-grade intraepithelial lesions in either group.
4. Discussion
Our pilot study results add to a rich body of literature
demonstrating that HPV types other than those included
in the quadrivalent vaccine are being encountered in many
African countries. In a recent international meta-analysis,
including 5 African studies, Cliﬀord et al. found that the
proportion of HPV prevalence attributable to HPV-16 was
lower in HIV-positive women, including those with HGSIL,
than in the general population and that other high-risk
types (e.g., HPV-18, 31, 33, 51, 52, and 58) were also
prevalent [26, 27]. Mu˜ noz et al. demonstrated from pooled
analyses of data from an international survey of HPV types
in cervical cancer and from a multicenter case-control study
that a higher proportion than usual of HPV-45 was found
in sub-Saharan Africa [14]. Similarly, Sahasrabuddhe et al
performed HPV typing on 145 nonpregnant HIV-positive
Zambian women and found that, among the high-risk
types, HPV types 52, 58, and 53 were more common than
H P Vt y p e s1 6a n d1 8[ 28]. As many others have recently
demonstrated,HPVsubtypesotherthan16and18areclearly
playing a role in international HPV prevalence [29–32].4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Demographics.
Antenatal group N = 36 Support group N = 29 P-value
Age, median (range) 27 (23–36) 29 (26–32) .960
HIV positive % 8.3 100.0 .001
Cell phone % 75 58.6 .550
School in median no. Yrs, (range) 12 (0–21) 11 (6–19) .164
Married % 80.6 75.9 .522
No. wives, median (range) 1.0 (1–3) 1.0 (1–2) .524
Age at sexual debut, median (range) 18 (13–37) 18 (13–21) .310
No. partners, median (range) 1.0 (0–7) 1.0 (0–3) .325
Condoms,% .001
Never 51.5 10.7
Seldom 30.3 35.7
Often 12.1 35.7
Don’t Know 6.1 17.9
Table 2: Inﬂuence of HIV on HPV.
H I VN E G H I VP O S P-value
Any HPV (%) 15/29 (51.7) 26/32 (81.3) .014
>1 HPV TYPE (%) 11/29 (37.9) 24/32 (75.0) .003
High-risk HPV (%) 10/29 (34.5) 22/32 (68.8) .007
Types 6, 11, 16, or 18 present (%) 8/29 (27.6) 20/32 (62.5) .006
Types 16 or 18 present (%) 1/29 (3.5%) 6/32 (18.8) .061
Table 3: Thin prep ﬁndings.
NEG ASCUS LGSIL HGSIL
HIV POS
HR HPV+ 10 6 6 0
HR HPV− 10 0 0 0
HIV NEG
HR HPV+ 5 2 2 0
HR HPV− 16 1 2 0
HIV+ P=.013, HIV− P=.235, ASCUS: atypical squamous cells of
unknown signiﬁcance, LGSIL: low-grade squamous intraepithelial lesion,
HGSIL: high-grade squamous intraepithelial lesion, HR: high risk.
We found that the known oncogenic subtypes 45 and 58
were signiﬁcantly more prevalent than subtypes 16 and 18.
With increasing numbers of HIV-infected women in sub-
Saharan Africa now accessing life-prolonging antiretroviral
therapy, these women may now live long enough to be
at higher risk for developing cervical cancer [33, 34]. Our
ﬁnding has implications in the incipient application of the
prophylactic HPV vaccine containing the high risk subtypes
1 6a n d1 8i nc o u n t r i e sw h e r ec e r v i c a lc a n c e rp r e v a l e n c e
continues to be much higher than it is here in the United
States [35]. There has been encouraging yet far from
conclusive data to suggest that, because of closely related
DNA genomes between HPV types, there may be HPV
type cross-protection aﬀorded by the quadrivalent vaccine
[36, 37].
We noted a prevalence of HPV in our study of 67.2%
with 85.4% having more than one HPV type and 78.0%
having one of the high risk subtypes. This is at the higher
end of previous comprehensive estimates in similar HIV-
positive female populations [29–32, 38, 39] which have
reported 12–79% of study participants with more than one
HPV subtype. Our high prevalence may be reﬂective of the
immunosuppression caused by concomitant infection with
HIV.Unfortunately,ourstudydidnotincludemeasurements
of either CD4 counts or HIV viral RNA to further investigate
thispossibility. MostHIV-positive womeninourstudynever
had such testing and thus analyses between HPV and HIV
progression were not feasible.
Although our study set out to determine possible
interactions between HPV, HIV, and other reproductive
tract infections, we were not able to accurately assess our
participants for gonorrhea or chlamydia due to a delay in
transferring the Thin Prep samples to appropriate testing
mediawithin7days,asisrecommendedbythemanufacturer
(Cobas Amplicor CT/NG Test, Hoﬀmann-La Roche Inc,
Basel, Switzerland). However, we did not detect a signiﬁcant
number of syphilis, trichomonas, bacterial vaginosis, or
vaginal candidiasis infections (data not shown). Our study is
further limited by the small number of participants enrolled
as it was designed as a pilot study.
We were still able to demonstrate, however, that HIV-
positive women are more likely to test positive for HPV,
have more than one HPV type, and to be infected with high
risk HPV than their HIV-negative counterparts. This may
be explained by the impact of HIV on the host’s immune
system resulting in impaired HPV clearance, leading to
chronic HPV infection. The higher number of HPV types
encountered by the HIV-positive women in our study mayInfectious Diseases in Obstetrics and Gynecology 5
be attributed to HIV-mediated upregulation and persistence
of HPV [39–41] or repeated HPV exposure in the setting of
severe immunosuppresion.
Even after controlling for the eﬀect of high risk HPV on
Thin Prep ﬁndings, HIV was still associated with ASCUS or
LGSIL on Thin Prep analyses. We cannot explain why no
participants demonstrated HGSIL, as previous studies from
Senegal (11%) and Burkina Faso (3.8%) did demonstrate
a signiﬁcant number of HIV positive women with HR-
HPV to have HGSIL [30, 38]. Fortunately, ASCUS or LGSIL
lesionsaremorelikelytoregressratherthanprogresstowards
cervical cancer. Our study was not designed to conduct
repeattestingforHPVwhichwouldallowustofurtherassess
progression of cervical lesions or assess whether previously
noted HPV types persisted or were cleared and whether new
HPV types would be encountered.
Overall our pilot study includes Cameroon in the
growing list of African countries where HPV types diﬀer
from those currently included in the prophylactic vaccine.
With increasing numbers of women living with HIV longer,
cervical cancer has the potential to increase in incidence
and prevalence in countries such as Cameroon. Further
studies are needed to assess whether the current vaccine will
be eﬀective in cervical cancer prevention programs in this
region.
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